The 4th annual Cancer Vaccines conference will strengthen knowledge of targeted immunotherapies taking the foreground in revolutionizing cancer vaccines as well as look at the practicalities towards achieving sustained immune response.
SMi Group have worked closely with a leading panel of experts such as GSK Vaccines, Vaccinogen, The National Cancer Institute and Kings College London, to create a programme that will expand scientific horizons in topics such as formulation development, tumour genetic heterogeneity, fully personalised cancer treatment, combination therapies, gene editing for immunotherapy, plus much more!
Featured Speakers Include:
Prof. Farzin Farzaneh, Professor of Molecular Medicine, Kings College London
Michael Hanna, Chairman & CEO, Vaccinogen
Derek O’Hagan, Global Head of Vaccine 91AV & Formulation, GSK
Sebastian Kreiter, VP Immunotherapy, BioNTech RNA Pharmaceuticals
Vaios Karanikas, Biomarker & Experimental Medicine Leader, Tumor Immunology, Roche
Thomas Felzmann, CEO, Activartis Biotech GmbH
Peter L. Andersen, VP Vaccine R&D, Statens Serum Institut
Ravi A. Madan, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute
Prof. Dr. Dirk Jager, Medical Oncology, National Center for Tumor Diseases, University Hospital Heidelberg
Reasons to Attend:
Address the provocative issue of tumour genetic heterogeneity in immunotherapy
Understand the angiogenic process in both normal and tumour and development
Gain key industry perspective in combination therapies to advance immune-oncology vaccines and enhance patient outcomes
Envision RNA - vaccinology for building the next-generation of RNA immunogens
Immerse yourself into a universe of new insights as we explore cutting edge developments in areas such as CAR T-Cell Therapy, Oncolytic viral therapies, Gene-therapy and Adoptive T-Cell transfer
SMi Group have worked closely with a leading panel of experts such as GSK Vaccines, Vaccinogen, The National Cancer Institute and Kings College London, to create a programme that will expand scientific horizons in topics such as formulation development, tumour genetic heterogeneity, fully personalised cancer treatment, combination therapies, gene editing for immunotherapy, plus much more!
Featured Speakers Include:
Prof. Farzin Farzaneh, Professor of Molecular Medicine, Kings College London
Michael Hanna, Chairman & CEO, Vaccinogen
Derek O’Hagan, Global Head of Vaccine 91AV & Formulation, GSK
Sebastian Kreiter, VP Immunotherapy, BioNTech RNA Pharmaceuticals
Vaios Karanikas, Biomarker & Experimental Medicine Leader, Tumor Immunology, Roche
Thomas Felzmann, CEO, Activartis Biotech GmbH
Peter L. Andersen, VP Vaccine R&D, Statens Serum Institut
Ravi A. Madan, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute
Prof. Dr. Dirk Jager, Medical Oncology, National Center for Tumor Diseases, University Hospital Heidelberg
Reasons to Attend:
Address the provocative issue of tumour genetic heterogeneity in immunotherapy
Understand the angiogenic process in both normal and tumour and development
Gain key industry perspective in combination therapies to advance immune-oncology vaccines and enhance patient outcomes
Envision RNA - vaccinology for building the next-generation of RNA immunogens
Immerse yourself into a universe of new insights as we explore cutting edge developments in areas such as CAR T-Cell Therapy, Oncolytic viral therapies, Gene-therapy and Adoptive T-Cell transfer
